People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bonum Therapeutics, Inc. | — | Biotechnology | Series C | $46.2M | $746.8M | 2022 |
| EpiBiologics, Inc. | — | Biotechnology | Series B | $30.0M | $570.2M | 2022 |
Samuel Bjork at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Samuel Bjork on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mitchell Mutz | 2 | 5 |
| Alexandra Cantley | 1 | 8 |
| NICHOLAS WALROD | 1 | 8 |
| John McKearn | 1 | 6 |
| James Wells | 1 | 4 |
| John Mulligan | 1 | 3 |
| Jason Coloma | 1 | 3 |
| Karl Handelsman | 1 | 3 |
| Diane Hollenbaugh | 1 | 3 |
| Neela Patel | 1 | 2 |
| Monique Schiersing | 1 | 2 |
| Craig Lichtenstein | 1 | 1 |
| Michael Kavanaugh | 1 | 1 |
| Seiji Miyahara | 1 | 1 |
| Ann Lee-Karlon | 1 | 1 |
| Rami Hannoush | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.